Cell Therapy for Refractory Angina: A Reappraisal

Beatrice Bassetti, Patrizia Nigro, Valentina Catto, Laura Cavallotti, Stefano Righetti, Felice Achilli, Paolo Scacciatella, Corrado Carbucicchio, Giulio Pompilio

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Cardiac cell-based therapy has emerged as a novel therapeutic option for patients dealing with untreatable refractory angina (RA). However, after more than a decade of controlled studies, no definitive consensus has been reached regarding clinical efficacy. Although positive results in terms of surrogate endpoints have been suggested by early and phase II clinical studies as well as by meta-analyses, the more recent reports lacked the provision of definitive response in terms of hard clinical endpoints. Regrettably, pivotal trials designed to conclusively determine the efficacy of cell-based therapeutics in such a challenging clinical condition are therefore still missing. Considering this, a comprehensive reappraisal of cardiac cell-based therapy role in RA seems warranted and timely, since a number of crucial cell- and patient-related aspects need to be systematically analysed. As an example, the large variability in efficacy endpoint selection appears to be a limiting factor for the advancement of cardiac cell-based therapy in the field. This review will provide an overview of the key elements that may have influenced the results of cell-based trials in the context of RA, focusing in particular on the understanding at which the extent of angina-related endpoints may predict cell-based therapeutic efficacy.

Original languageEnglish
Pages (from-to)5648690
JournalStem Cells International
Volume2017
DOIs
Publication statusPublished - 2017

Fingerprint

Cell- and Tissue-Based Therapy
Meta-Analysis
Therapeutics
Cell Count
Biomarkers

Keywords

  • Journal Article
  • Review

Cite this

Cell Therapy for Refractory Angina : A Reappraisal. / Bassetti, Beatrice; Nigro, Patrizia; Catto, Valentina; Cavallotti, Laura; Righetti, Stefano; Achilli, Felice; Scacciatella, Paolo; Carbucicchio, Corrado; Pompilio, Giulio.

In: Stem Cells International, Vol. 2017, 2017, p. 5648690.

Research output: Contribution to journalReview article

Bassetti, Beatrice ; Nigro, Patrizia ; Catto, Valentina ; Cavallotti, Laura ; Righetti, Stefano ; Achilli, Felice ; Scacciatella, Paolo ; Carbucicchio, Corrado ; Pompilio, Giulio. / Cell Therapy for Refractory Angina : A Reappraisal. In: Stem Cells International. 2017 ; Vol. 2017. pp. 5648690.
@article{37fa612ea87347679508c7219355f218,
title = "Cell Therapy for Refractory Angina: A Reappraisal",
abstract = "Cardiac cell-based therapy has emerged as a novel therapeutic option for patients dealing with untreatable refractory angina (RA). However, after more than a decade of controlled studies, no definitive consensus has been reached regarding clinical efficacy. Although positive results in terms of surrogate endpoints have been suggested by early and phase II clinical studies as well as by meta-analyses, the more recent reports lacked the provision of definitive response in terms of hard clinical endpoints. Regrettably, pivotal trials designed to conclusively determine the efficacy of cell-based therapeutics in such a challenging clinical condition are therefore still missing. Considering this, a comprehensive reappraisal of cardiac cell-based therapy role in RA seems warranted and timely, since a number of crucial cell- and patient-related aspects need to be systematically analysed. As an example, the large variability in efficacy endpoint selection appears to be a limiting factor for the advancement of cardiac cell-based therapy in the field. This review will provide an overview of the key elements that may have influenced the results of cell-based trials in the context of RA, focusing in particular on the understanding at which the extent of angina-related endpoints may predict cell-based therapeutic efficacy.",
keywords = "Journal Article, Review",
author = "Beatrice Bassetti and Patrizia Nigro and Valentina Catto and Laura Cavallotti and Stefano Righetti and Felice Achilli and Paolo Scacciatella and Corrado Carbucicchio and Giulio Pompilio",
year = "2017",
doi = "10.1155/2017/5648690",
language = "English",
volume = "2017",
pages = "5648690",
journal = "Stem Cells International",
issn = "1687-966X",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - Cell Therapy for Refractory Angina

T2 - A Reappraisal

AU - Bassetti, Beatrice

AU - Nigro, Patrizia

AU - Catto, Valentina

AU - Cavallotti, Laura

AU - Righetti, Stefano

AU - Achilli, Felice

AU - Scacciatella, Paolo

AU - Carbucicchio, Corrado

AU - Pompilio, Giulio

PY - 2017

Y1 - 2017

N2 - Cardiac cell-based therapy has emerged as a novel therapeutic option for patients dealing with untreatable refractory angina (RA). However, after more than a decade of controlled studies, no definitive consensus has been reached regarding clinical efficacy. Although positive results in terms of surrogate endpoints have been suggested by early and phase II clinical studies as well as by meta-analyses, the more recent reports lacked the provision of definitive response in terms of hard clinical endpoints. Regrettably, pivotal trials designed to conclusively determine the efficacy of cell-based therapeutics in such a challenging clinical condition are therefore still missing. Considering this, a comprehensive reappraisal of cardiac cell-based therapy role in RA seems warranted and timely, since a number of crucial cell- and patient-related aspects need to be systematically analysed. As an example, the large variability in efficacy endpoint selection appears to be a limiting factor for the advancement of cardiac cell-based therapy in the field. This review will provide an overview of the key elements that may have influenced the results of cell-based trials in the context of RA, focusing in particular on the understanding at which the extent of angina-related endpoints may predict cell-based therapeutic efficacy.

AB - Cardiac cell-based therapy has emerged as a novel therapeutic option for patients dealing with untreatable refractory angina (RA). However, after more than a decade of controlled studies, no definitive consensus has been reached regarding clinical efficacy. Although positive results in terms of surrogate endpoints have been suggested by early and phase II clinical studies as well as by meta-analyses, the more recent reports lacked the provision of definitive response in terms of hard clinical endpoints. Regrettably, pivotal trials designed to conclusively determine the efficacy of cell-based therapeutics in such a challenging clinical condition are therefore still missing. Considering this, a comprehensive reappraisal of cardiac cell-based therapy role in RA seems warranted and timely, since a number of crucial cell- and patient-related aspects need to be systematically analysed. As an example, the large variability in efficacy endpoint selection appears to be a limiting factor for the advancement of cardiac cell-based therapy in the field. This review will provide an overview of the key elements that may have influenced the results of cell-based trials in the context of RA, focusing in particular on the understanding at which the extent of angina-related endpoints may predict cell-based therapeutic efficacy.

KW - Journal Article

KW - Review

U2 - 10.1155/2017/5648690

DO - 10.1155/2017/5648690

M3 - Review article

C2 - 29375624

VL - 2017

SP - 5648690

JO - Stem Cells International

JF - Stem Cells International

SN - 1687-966X

ER -